FRANKFURT (Reuters) – Unlisted German biotech firm CureVac will become the second company to launch human trials of an experimental coronavirus vaccine in the country, Germany’s vaccines regulator said on Wednesday.
Reuters reported on Tuesday that the watchdog, the Paul Ehrlich Institut, would approve testing on humans of the experimental vaccine. [L8N2DT5XC]
Reporting by Ludwig Burger; editing by Thomas Seythal
Our Standards:The Thomson Reuters Trust Principles.